This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zyloprim

Nestle S.A.

Drug Names(s): allopurinol

Description: Allopurinol is a structural isomer of the natural purine hypoxanthine. It inhibits xanthine oxidase, an enzyme involved in the metabolism of hypoxanthine to xanthine, with the production of uric acid. Uric acid crystals are responsible for gout. Inhibition of the enzyme also leads to higher levels of certain purines that exert a negative feedback on purine biosynthesis.

Deal Structure: Allopurinol is marketed by Prometheus Labs in the United States, while in other countries it continues to be marketed by GlaxoSmithKline.

In May 2011, Prometheus Laboratories announced that it has entered into a definitive agreement to be acquired by Nestl Health Science S.A., a wholly-owned subsidiary of Nestl S.A., for an undisclosed amount. Financial terms were not disclosed. The acquisition was completed in July 2011.

Partners: GlaxoSmithKline plc


Zyloprim News

Pink Sheet Nabi


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug